174 related articles for article (PubMed ID: 21781284)
1. Determination of noscapine's localization and interaction with the tubulin-α/β heterodimer.
Alisaraie L; Tuszynski JA
Chem Biol Drug Des; 2011 Oct; 78(4):535-46. PubMed ID: 21781284
[TBL] [Abstract][Full Text] [Related]
2. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid.
Naik PK; Chatterji BP; Vangapandu SN; Aneja R; Chandra R; Kanteveri S; Joshi HC
J Comput Aided Mol Des; 2011 May; 25(5):443-54. PubMed ID: 21544622
[TBL] [Abstract][Full Text] [Related]
3. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
4. Rational design of the microtubule-targeting anti-breast cancer drug EM015.
Aneja R; Lopus M; Zhou J; Vangapandu SN; Ghaleb A; Yao J; Nettles JH; Zhou B; Gupta M; Panda D; Chandra R; Joshi HC
Cancer Res; 2006 Apr; 66(7):3782-91. PubMed ID: 16585205
[TBL] [Abstract][Full Text] [Related]
5. Structural investigations into the binding mode of a novel noscapine analogue, 9-(4-vinylphenyl) noscapine, with tubulin by biochemical analyses and molecular dynamic simulations.
Mahaddalkar T; Naik PK; Choudhary S; Manchukonda N; Kantevari S; Lopus M
J Biomol Struct Dyn; 2017 Aug; 35(11):2475-2484. PubMed ID: 27576773
[No Abstract] [Full Text] [Related]
6. Structural Basis of Noscapine Activation for Tubulin Binding.
Oliva MA; Prota AE; Rodríguez-Salarichs J; Bennani YL; Jiménez-Barbero J; Bargsten K; Canales Á; Steinmetz MO; Díaz JF
J Med Chem; 2020 Aug; 63(15):8495-8501. PubMed ID: 32657585
[TBL] [Abstract][Full Text] [Related]
7. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
[TBL] [Abstract][Full Text] [Related]
8. A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation.
Ghaly PE; Abou El-Magd RM; Churchill CD; Tuszynski JA; West FG
Oncotarget; 2016 Jun; 7(26):40518-40530. PubMed ID: 27777381
[TBL] [Abstract][Full Text] [Related]
9. Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site.
Naik PK; Santoshi S; Rai A; Joshi HC
J Mol Graph Model; 2011 Jun; 29(7):947-55. PubMed ID: 21530342
[TBL] [Abstract][Full Text] [Related]
10. Rational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents.
Manchukonda NK; Naik PK; Santoshi S; Lopus M; Joseph S; Sridhar B; Kantevari S
PLoS One; 2013; 8(10):e77970. PubMed ID: 24205049
[TBL] [Abstract][Full Text] [Related]
11. In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin).
Naik PK; Lopus M; Aneja R; Vangapandu SN; Joshi HC
J Comput Aided Mol Des; 2012 Feb; 26(2):233-47. PubMed ID: 22170255
[TBL] [Abstract][Full Text] [Related]
12. Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
Bennani YL; Gu W; Canales A; Díaz FJ; Eustace BK; Hoover RR; Jiménez-Barbero J; Nezami A; Wang T
J Med Chem; 2012 Mar; 55(5):1920-5. PubMed ID: 22320354
[TBL] [Abstract][Full Text] [Related]
13. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.
Landen JW; Hau V; Wang M; Davis T; Ciliax B; Wainer BH; Van Meir EG; Glass JD; Joshi HC; Archer DR
Clin Cancer Res; 2004 Aug; 10(15):5187-201. PubMed ID: 15297423
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction of N-3-Br-benzyl-noscapine and docetaxel abrogates oncogenic potential of breast cancer cells.
Dash SG; Kantevari S; Pandey SK; Naik PK
Chem Biol Drug Des; 2021 Sep; 98(3):466-479. PubMed ID: 34107169
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
Aneja R; Vangapandu SN; Lopus M; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2006 Jun; 69(6):1801-9. PubMed ID: 16517755
[TBL] [Abstract][Full Text] [Related]
16. A Comprehension into Target Binding and Spatial Fingerprints of Noscapinoid Analogues as Inhibitors of Tubulin.
Mandavi S; Verma SK; Banjare L; Dubey A; Bhatt R; Thareja S; Jain AK
Med Chem; 2021; 17(6):611-622. PubMed ID: 31951171
[TBL] [Abstract][Full Text] [Related]
17. Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms.
Nourbakhsh F; Askari VR
Biofactors; 2021 Nov; 47(6):975-991. PubMed ID: 34534373
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death.
Aneja R; Vangapandu SN; Lopus M; Viswesarappa VG; Dhiman N; Verma A; Chandra R; Panda D; Joshi HC
Biochem Pharmacol; 2006 Aug; 72(4):415-26. PubMed ID: 16780803
[TBL] [Abstract][Full Text] [Related]
19. Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath S; Mahaddalkar T; Reddy Nagireddy PK; Sridhar B; Kantevari S; Lopus M
Pharmacol Rep; 2019 Feb; 71(1):48-53. PubMed ID: 30465924
[TBL] [Abstract][Full Text] [Related]
20. Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to γ-tubulin dimer.
Suri C; Naik PK
SAR QSAR Environ Res; 2015 Jun; 26(6):507-19. PubMed ID: 26274780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
